Disorders of Coagulation in Stroke

Salina P. Waddy

doi:10.1055/s-2006-933309

Seminars in Neurology, Table of Contents

Semin Neurol 2006; 26(1): 057-064
DOI: 10.1055/s-2006-933309

Disorders of Coagulation in Stroke

Salina P. Waddy¹

¹Assistant Professor in Neurology, Emory University, Atlanta, Georgia

Abstract

ABSTRACT

The roles of the coagulopathies in thrombosis have been well established; however, the role in ischemic stroke is poorly understood. This article reviews the recent advances in the genetics of coagulation, the recently identified interactive roles of the coagulation and anticoagulation proteins, and the literature supporting protein dysregulation as a causative agent in cerebral venous thrombosis and ischemic stroke.

KEYWORDS

Coagulation - stroke - protein

Full Text

References

REFERENCES

1 Spronk H M, Govers-Riemslag J W, ten Cate H. The blood coagulation system as a molecular machine. Bioessays. 2003; 25 1220-1228
2 Haberl R L, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders. Cerebrovasc Dis. 1995; 5 391-396
3 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995; 15 783-785
4 Mann K G, Kalafatis M. Factor V: a combination of Dr Jekyll and Mr Hyde. Blood. 2003; 101 20-30
5 Lutze G, Frick U, Topfer G, Urbahn H. Hereditaere Dysprothrombinaemie mit geringer Blutungsneigung (Prothrombin Magdeburg). Dtsch Med Wochenschr. 1989; 114 288-292
6 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the 3-prime-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996; 88 3698-3703
7 Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost. 2003; 1 3-9
8 Nicolaes G A, Tans G, Thomassen M C et al.. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem. 1995; 270 21158-21166
9 Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost. 2003; 1 3-9
10 Váradi K, Rosing J, Tans G et al.. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor V^R506Q mutation. Thromb Haemost. 1996; 76 208-214
11 Thorelli E, Kaufman R J, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood. 1999; 93 2552-2558
12 Ridker P M, Miletich J P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332 912-917
13 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995; 15 783-785
14 Press R D, Liu X-Y, Beamer N et al.. Ischaemic stroke in the elderly. Role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996; 27 44-48
15 Castaman G, Tosetto A, Ruggeri M, Rodeghiero F. Pseudohomozygosity for activated protein C resistance is a risk factor for venous thrombosis. Br J Haematol. 1999; 106 232-236
16 Castoldi E, Brugge J M, Nicolaes G A et al.. Impaired APC-cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood. 2004; 103 4173-4179
17 Bernardi F, Faioni E M, Castoldi E et al.. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood. 1997; 90 1552-1557
18 Castaman G, Lunghi B, Missiaglia E, Bernardi F, Rodeghiero F. Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299Arg substitutions in factor V. Br J Haematol. 1997; 99 257-261
19 Williamson D, Brown K, Luddington R et al.. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998; 91 1140-1144
20 Chan W P, Lee C K, Kwong Y L et al.. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood. 1998; 91 1135-1139
21 Gehring N H, Frede U, Neu-Yilik G et al.. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001; 28 389-392
22 Rosendaal F R. High levels of factor VIII and venous thrombosis. Thromb Haemost. 2000; 83 1-2
23 Bertina R M. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb. 2003; 33 395-400
24 Sebire G, Tabarki B, Saunders D E et al.. Cerebral venous sinus thrombosis in children: risk factors, presentation, diagnosis and outcome. Brain. 2005; 128 477-489
25 Williamson D, Brown K, Luddington R, Baglin C, Baglin T. Factor V Cambridge: a new mutation (Arg306→Thr) associated with resistance to activated protein C. Blood. 1998; 91 1140-1144
26 Kalafatis M, Simioni P, Tormene D et al.. Isolation and characterization of an anti-factor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood. 2002; 99 3985-3992
27 Henkens C M, Bom V J, van der Meer J. Lowered APC-sensitivity ratio related to increased factor VIII-clotting activity. Thromb Haemost. 1995; 74 1198-1199
28 Laffan M A, Manning R. The influence of factor VIII on measurement of activated protein C resistance. Blood Coagul Fibrinolysis. 1996; 7 761-765
29 Reitsma P H, Bernardi F, Doig R G et al.. Protein C deficiency: a database of mutations, 1995 update. On behalf of the Subcommittee on Plasma Coagulation Inhibitors of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1995; 73 876-889
30 Reitsma P H. Protein C deficiency: summary of the 1995 database update. Nucleic Acids Res. 1996; 24 157-159
31 Gladson C L, Scharrer I, Hach V et al.. The frequency of type 1 heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost. 1988; 59 18-22
32 Grewal R P, Goldberg M A. Stroke in protein C deficiency. Am J Med. 1990; 89 538-539
33 Kohler J, Kasper J, Witt I et al.. Ischaemic stroke due to protein C deficiency. Stroke. 1990; 21 1077-1080
34 Camerlingo M, Finazzi G, Caato L et al.. Inherited protein C deficiency and non-haemorrhagic arterial stroke in young adults. Neurology. 1991; 41 1371-1373
35 Thomas D P, Roberts H R. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997; 126 638-644
36 Martinelli I, Mannucci P M, De Stefano V et al.. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood. 1998; 92 2353-2358
37 Kalafatis M, Rand M D, Mann K G. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem. 1994; 269 31869-31880
38 Nicolaes GAF, Tans G, Christella M et al.. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor Va R506Q by activated protein C. J Biol Chem. 1995; 270 21158-21166
39 Heeb M J, Mesters R M, Tans G, Rosing J, Griffin J H. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem. 1993; 268 2872-2877
40 Hackeng T M, van't Veer C, Meijers J C, Bouma B N. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994; 269 21051-21058
41 Koppelman S J, Hackeng T M, Sixma J J, Bouma B N. Inhibition of the intrinsic factor X activating complex by protein S: evidence for a specific binding of protein S to factor VIII. Blood. 1995; 86 1062-1071
42 van Wijnen M, Stam J G, van't Veer C et al.. The interaction of protein S with the phospholipid surface is essential for the activated protein C-independent activity of protein S. Thromb Haemost. 1996; 76 397-403
43 Dahlbäck B. Protein S and C4b-binding protein: components involved in the regulation of the protein C anticoagulant system. Thromb Haemost. 1991; 66 49-61
44 van de Poel R H, Meijers J C, Bouma B N. C4b-binding protein inhibits the factor V-dependent but not the factor V-independent cofactor activity of protein S in the activated protein C-mediated inactivation of factor VIIIa. Thromb Haemost. 2001; 85 761-765
45 Rezende S M, Simmonds R E, Lane D A. Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood. 2004; 103 1192-1201
46 Gandrille S, Borgel D, Sala N et al.. Protein S deficiency: a database of mutations-summary of the first update. For the Plasma Coagulation Inhibitors Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2000; 84 918
47 Bertina R M. Nomenclature proposal for protein S deficiency. XXXVI Annual meeting of the Scientific and Standardization Committee of the ISTH Barcelona, Spain; 1990
48 Israels S J, Seshia S S. Childhood stroke associated with protein C or protein S deficiency. J Pediatr. 1987; 111 562-564
49 Barinagarrementeria F, Cant A, Cant-Brio C et al.. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke. 1994; 25 287-290
50 Mayer S A, Sacco R L, Hurlet-Jensen A, Shi T, Mohr J P. Free protein S deficiency in acute ischemic stroke: a case-control study. Stroke. 1993; 24 224-227
51 Kurnik K, Kosch A, Sträter R et al.. Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke. Stroke. 2003; 34 2887-2892
52 Green D, Otoya J, Oriba H, Rovner R. Protein S deficiency in middle-aged women with stroke. Neurology. 1992; 42 1029-1033
53 Golub B M, Sibony P A, Coller B S. Protein S deficiency associated with central retinal artery occlusion. Arch Ophthal. 1990; 108 918
54 Hakimi K N, Massagli T L. Anterior spinal artery syndrome in two children with genetic thrombotic disorders. J Spinal Cord Med. 2005; 28 69-73
55 Espinosa-Parrilla Y, Morell M, Souto J C et al.. Protein S gene analysis reveals the presence of a cosegregating mutation in most pedigrees with type I but not type III PS deficiency. Hum Mutat. 1999; 14 30-39
56 Makris M, Leach M, Beauchamp N J et al.. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood. 2000; 95 1935-1941
57 Borgel D, Gandrille S, Aiach M. Protein S deficiency. Thromb Haemost. 1997; 78 351-356
58 Restrepo L, McArthur J. Stroke and HIV infection. Stroke. 2003; 34 e176-e177
59 Stahl C P, Wideman C S, Spira T J, Haff E C, Hixon G J, Evatt B L. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood. 1993; 81 1801-1807
60 Majluf-Cruz A, Silva-Estrada M, Sanchez-Barboza R et al.. Venous thrombosis among patients with AIDS. Clin Appl Thromb Hemost. 2004; 10 19-25
61 Rosenberg R D, Damus P S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973; 248 6490-6505
62 Rosenberg J S, McKenna P W, Rosenberg R D. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975; 250 8883-8888
63 Seegers W H, Holt E. An antithrombin reaction related to prothrombin activation. Am J Physiol. 1954; 176 97
64 Biggs R, Denson K W, Akman N, Borrett R, Hadden M. Antithrombin III, antifactor X and heparin. Br J Haematol. 1970; 19 283-305
65 Damus P S, Hicks M, Rosenberg R D. Anticoagulant action of heparin. Nature. 1973; 246 355-357
66 Stead N, Kaplan A, Rosenberg R D. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 1976; 251 6481-6488
67 Olson S T, Björk I, Sheffer R, Craig P A, Shore J D, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992; 267 12528-12538
68 Stein P E, Carrell R W. What do dysfunctional serpins tell us about molecular mobility and disease?. Nat Struct Biol. 1995; 2 96-113
69 Vomberg P P, Breederveld C, Fluery P, Arts W F. Cerebral thromboembolism due to antithrombin III deficiency in two children. Neuropediatrics. 1987; 18 42-44
70 Simioni P, Zanardi S, Saracino A et al.. Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. J Med. 1992; 23 61-64
71 Arima T, Motomura M, Nishiura Y et al.. Cerebral infarction in a heterozygous with variant antithrombin III. Stroke. 1992; 23 1822-1825
72 Graham J A, Daly H M, Carson P J. Antithrombin III deficiency and cerebrovascular accidents in young adults. J Clin Pathol. 1992; 45 921-922
73 Martinez H R, Rangel Guerra R A, Marfil L J. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke. 1993; 24 19-25
74 Barinagarrementeria F, Cantu-Brito C, De La Pena A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study. Stroke. 1994; 25 287-290
75 Ernerudh J, Olsson J E, von Schenck H. Antithrombin-III deficiency in ischemic stroke. Stroke. 1990; 21 967
76 Munts A G, van Genderen P J, Dippel D W, van Kooten F, Koudstaal P J. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol. 1998; 245 21-25
77 Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Eisenberg P R, Miletich J. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995; 332 912-917
78 Markus H S, Hambley H. Neurology and the blood: haematological abnormalities in ischaemic stroke. J Neurol Neurosurg Psychiatry. 1998; 64 150-159
79 Haberl R L, Biniasch O, Ott M, Peinemann A, Wick M, Kempter B. Infrequency of stroke caused by specific coagulation disorders. Cerebrovasc Dis. 1995; 5 391-396
80 Catto A, Carter A, Ireland H et al.. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol. 1995; 15 783-785
81 Press R D, Liu X, Beamer N, Coull B M. Ischemic stroke in the elderly: role of the common factor V mutation causing resistance to activated protein C. Stroke. 1996; 27 44-48
82 Hankey G J, Eikelboom J W, van Bockxmeer F M, Lofthouse E, Staples N, Baker R. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke. 2001; 32 1793-1799
83 Jerrard-Dunne P, Evans A, McGovern R et al.. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke. 2003; 34 1821-1827
84 Martinez H R, Rangel Guerra R A, Marfil L J. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke. 1993; 24 19-25
85 Barinagarrementeria F, Cantu-Brito C, De La Peria A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke: a prospective study. Stroke. 1994; 25 287-290
86 Munts A G, van Genderen P J, Dippel D W, van Kooten F, Koudstaal P J. Coagulation disorders in young adults with acute cerebral ischaemia. J Neurol. 1998; 245 21-25
87 Kroon U B, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost. 1994; 71 420-423
88 Shen Y M, Frenkel E P. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost. 2004; 10 277-280

Salina P WaddyM.D.

Department of Neurology, Emory University, Woodruff Memorial Research Building, Suite 600, 101 Woodruff Circle, Atlanta, GA 30322